地诺孕素治疗子宫腺肌病相关性疼痛的研究进展

doi:10.12280/gjfckx.20250166

国际妇产科学杂志 ›› 2025, Vol. 52 ›› Issue (3): 246-251.doi: 10.12280/gjfckx.20250166

• 普通妇科疾病及相关研究: 综述 • 上一篇下一篇

地诺孕素治疗子宫腺肌病相关性疼痛的研究进展

严莹, 杨洋, 钟华, 梁炎春^△()

530025 南宁，中山大学附属第一医院广西医院妇产科（严莹，杨洋，钟华，梁炎春）；中山大学附属第一医院妇产科，广东省妇产疾病临床医学研究中心（梁炎春）

收稿日期:2025-02-24 出版日期:2025-06-15 发布日期:2025-06-19
通讯作者: 梁炎春 E-mail:lyanchun@mail.sysu.edu.cn
作者简介:^△审校者
基金资助:
广东省基础与应用基础研究基金项目(2023A1515010018);广东省基础与应用基础研究基金企业联合基金（公共卫生与医药健康领域）项目(2022A1515220143);中山大学附属第一医院广西医院青年科学基金项目(YQ2025001);2023年揭阳市科技创新发展专项引导项目（公益技术研究与应用示范）(DZX083);揭阳市科技计划项目（卫生医疗类项目）(2022wsyl016);2021年中山大学附属第一医院柯麟新星人才计划(R08013)

Research Progress on the Treatment of Adenomyosis-Related Pain with Dienogest

YAN Ying, YANG Yang, ZHONG Hua, LIANG Yan-chun^△()

Department of Obstetrics and Gynecology, Guangxi Hospital Division of The First Affiliated Hospital, Sun Yat-sen University, Nanning 530025, China (YAN Ying, YANG Yang, ZHONG Hua, LIANG Yan-chun);Department of Obstetrics and Gynecology, The First Affiliated Hospital of Sun Yat-sen University, Guangdong Provincial Clinical Research Center for Obstetrical and Gynecological Diseases, Guangzhou 510080, China (LIANG Yan-chun)

Received:2025-02-24 Published:2025-06-15 Online:2025-06-19
Contact: LIANG Yan-chun E-mail:lyanchun@mail.sysu.edu.cn

摘要/Abstract

摘要：

痛经是子宫腺肌病（adenomyosis，AM）的主要症状之一，AM相关性疼痛的发病涉及多种机制。地诺孕素作为AM相关性疼痛治疗的关键药物之一，在AM的长期管理中具有重要作用。基础研究表明，地诺孕素能通过有效抑制异位子宫内膜间质细胞增殖和炎症反应，促进凋亡，调控神经生长因子的表达和免疫微环境，抑制血管生成等多种作用机制，达到减轻炎症、降低疼痛过敏，控制AM进展的目的。临床研究证据进一步阐明地诺孕素在缓解AM相关性疼痛和改善子宫出血、控制子宫体积方面的效果优于其他药物，可以作为AM相关性疼痛的长期治疗药物，为进一步深入研究地诺孕素的作用机制和临床应用提供了科学依据。

关键词: 子宫腺肌病, 疼痛, 治疗, 疼痛管理, 地诺孕素

Abstract:

Dysmenorrhea is one of the main symptoms of adenomyosis (AM). The pathogenesis of AM-related pain involves multiple mechanisms. Dienogest, as one of the key drugs for the treatment of AM-related pain, plays an important role in the long-term management of AM. Basic research shows that dienogest can achieve the goals of reducing inflammation, decreasing pain hypersensitivity, and controlling the progression of AM through multiple mechanisms of action, such as inhibiting the proliferation and inflammatory response of ectopic endometrial stromal cells, promoting apoptosis, regulating the expression of nerve growth factors and the immune microenvironment, and inhibiting angiogenesis. Clinical research evidence further clarifies that dienogest is more effective than other drugs in relieving AM-related pain, improving uterine bleeding, and controlling uterine volume. It can be used as a long-term treatment drug for AM-related pain, providing a scientific basis for further in-depth research on the mechanism of action and clinical application of dienogest.

Key words: Adenomyosis, Pain, Therapy, Pain management, Dienogest

严莹, 杨洋, 钟华, 梁炎春. 地诺孕素治疗子宫腺肌病相关性疼痛的研究进展[J]. 国际妇产科学杂志, 2025, 52(3): 246-251.

YAN Ying, YANG Yang, ZHONG Hua, LIANG Yan-chun. Research Progress on the Treatment of Adenomyosis-Related Pain with Dienogest[J]. Journal of International Obstetrics and Gynecology, 2025, 52(3): 246-251.

参考文献 41

[1]	Dason ES, Maxim M, Sanders A, et al. Guideline No.437: Diagnosis and Management of Adenomyosis[J]. J Obstet Gynaecol Can, 2023, 45(6):417-429.e1 doi: 10.1016/j.jogc.2023.04.008.
[2]	Alcock MM. Defining pain: past, present, and future[J]. Pain, 2017, 158(4):761-762. doi: 10.1097/j.pain.0000000000000828. pmid: 28301403
[3]	Chen Q, Li YW, Wang S, et al. Clinical Manifestations Of Adenomyosis Patients With Or Without Pain Symptoms[J]. J Pain Res, 2019, 12:3127-3133. doi: 10.2147/JPR.S212117. pmid: 31814754
[4]	Volcheck MM, Graham SM, Fleming KC, et al. Central sensitization, chronic pain, and other symptoms: Better understanding, better management[J]. Cleve Clin J Med, 2023, 90(4):245-254. doi: 10.3949/ccjm.90a.22019.
[5]	Bourdon M, Santulli P, Jeljeli M, et al. Immunological changes associated with adenomyosis: a systematic review[J]. Hum Reprod Update, 2021, 27(1):108-129. doi: 10.1093/humupd/dmaa038. pmid: 33099635
[6]	Zhai J, Vannuccini S, Petraglia F, et al. Adenomyosis: Mechanisms and Pathogenesis[J]. Semin Reprod Med, 2020, 38(2-03):129-143. doi: 10.1055/s-0040-1716687. pmid: 33032339
[7]	Shi J, Xu Q, Yu S, et al. Perturbations of the endometrial immune microenvironment in endometriosis and adenomyosis: their impact on reproduction and pregnancy[J]. Semin Immunopathol, 2025, 47(1):16. doi: 10.1007/s00281-025-01040-1. pmid: 39966111
[8]	Cao Y, Yang D, Cai S, et al. Adenomyosis-associated infertility: an update of the immunological perspective[J]. Reprod Biomed Online, 2025, 50(5):104703. doi: 10.1016/j.rbmo.2024.104703.
[9]	Liu F, Liu L, Zheng J. Expression of annexin A2 in adenomyosis and dysmenorrhea[J]. Arch Gynecol Obstet, 2019, 300(3):711-716. doi: 10.1007/s00404-019-05205-w. pmid: 31183557
[10]	王舒, 甘卫冬, 金锦祥, 等. Slit-Robo细胞信号转导通路研究进展[J]. 生物化学与生物物理进展, 2022, 49(2):318-327. doi: 10.16476/j.pibb.2020.0329.
[11]	Nie J, Liu X, Zheng Y, et al. Increased immunoreactivity to SLIT/ROBO1 and its correlation with severity of dysmenorrhea in adenomyosis[J]. Fertil Steril, 2011, 95(3):1164-1167. doi: 10.1016/j.fertnstert.2010.09.027. pmid: 20970134
[12]	Chen Y, Zhu J, Chen L, et al. SFRP4+IGFBP5hi NKT cells induced neural-like cell differentiation to contribute to adenomyosis pain[J]. Front Immunol, 2022,13:945504. doi: 10.3389/fimmu.2022.945504.
[13]	Habiba M, Benagiano G, Guo SW. An Appraisal of the Tissue Injury and Repair (TIAR) Theory on the Pathogenesis of Endometriosis and Adenomyosis[J]. Biomolecules, 2023, 13(6):975. doi: 10.3390/biom13060975.
[14]	van Loo G, Bertrand M. Death by TNF: a road to inflammation[J]. Nat Rev Immunol, 2023, 23(5):289-303. doi: 10.1038/s41577-022-00792-3.
[15]	林燕丹, 潘琦文, 李建湘. 地诺孕素治疗子宫腺肌症痛经患者的临床效果及其作用机制研究[J]. 中国医药科学, 2024, 14(2):96-98,102. doi: 10.20116/j.issn2095-0616.2024.02.23.
[16]	Carrarelli P, Yen CF, Funghi L, et al. Expression of Inflammatory and Neurogenic Mediators in Adenomyosis[J]. Reprod Sci, 2017, 24(3):369-375. doi: 10.1177/1933719116657192. pmid: 27440813
[17]	Vannuccini S, Tosti C, Carmona F, et al. Pathogenesis of adenomyosis: an update on molecular mechanisms[J]. Reprod Biomed Online, 2017, 35(5):592-601. doi: 10.1016/j.rbmo.2017.06.016. pmid: 28693952
[18]	李雁, 张绍芬, 许琳娜. 子宫腺肌病病灶神经生长因子蛋白表达变化与神经植入及盆腔疼痛的关系[J]. 中华妇产科杂志, 2014, 49(2):120-124. doi: 10.3760/cma.j.issn.0529-567x.2014.02.009.
[19]	Li Y, Zhang D, Jin B, et al. Proteomic Analysis of Uterine Tissues During Peri-Implantation Period in Mice with Experimentally Induced Adenomyosis that Treated with anti-Ngf: Implications for Cell-Cell Adhesion and Metabolic Processes[J]. Reprod Sci, 2021, 28(1):207-217. doi: 10.1007/s43032-020-00262-y.
[20]	Yalaza C, Canacankatan N, Gürses, et al. Altered VEGF, Bcl-2 and IDH1 expression in patients with adenomyosis[J]. Arch Gynecol Obstet, 2020, 302(5):1221-1227. doi: 10.1007/s00404-020-05742-9. pmid: 32785780
[21]	Orazov MR, Nosenko EN, Radzinsky VE, et al. Proangiogenic features in chronic pelvic pain caused by adenomyosis[J]. Gynecol Endocrinol, 2016, 32(Suppl 2):7-10. doi: 10.1080/09513590.2016.1232902.
[22]	Stratopoulou CA, Donnez J, Dolmans MM. Origin and Pathogenic Mechanisms of Uterine Adenomyosis: What Is Known So Far[J]. Reprod Sci, 2021, 28(8):2087-2097. doi: 10.1007/s43032-020-00361-w. pmid: 33090375
[23]	Wang S, Duan H, Zhang Y, et al. Abnormal Activation of RhoA/ROCK-I Signaling in Junctional Zone Smooth Muscle Cells of Patients With Adenomyosis[J]. Reprod Sci, 2016, 23(3):333-341. doi: 10.1177/1933719115602764. pmid: 26335177
[24]	Jiang C, Gong W, Chen R, et al. RhoA/ROCK/ARHGAP26 signaling in the eutopic and ectopic endometrium is involved in clinical characteristics of adenomyosis[J]. J Int Med Res, 2018, 46(12):5019-5029. doi: 10.1177/0300060518789038. pmid: 30387365
[25]	Osuga Y, Fujimoto-Okabe H, Hagino A. Evaluation of the efficacy and safety of dienogest in the treatment of painful symptoms in patients with adenomyosis: a randomized, double-blind, multicenter, placebo-controlled study[J]. Fertil Steril, 2017, 108(4):673-678. doi: 10.1016/j.fertnstert.2017.07.021. pmid: 28911934
[26]	Vannuccini S, Luisi S, Tosti C, et al. Role of medical therapy in the management of uterine adenomyosis[J]. Fertil Steril, 2018, 109(3):398-405. doi: 10.1016/j.fertnstert.2018.01.013. pmid: 29566852
[27]	Kobayashi H. Efficacy, Adverse Events, and Challenges of Dienogest in the Management of Symptomatic Adenomyosis: A Comparison with Different Hormonal Treatments[J]. Gynecol Obstet Invest, 2023, 88(2):71-80. doi: 10.1159/000529185.
[28]	Ali MK, Hussein RS, Abdallah KS, et al. The use of dienogest in treatment of symptomatic adenomyosis: A systematic review and meta-analysis[J]. J Gynecol Obstet Hum Reprod, 2024, 53(7):102795. doi: 10.1016/j.jogoh.2024.102795.
[29]	Yamanaka A, Kimura F, Kishi Y, et al. Progesterone and synthetic progestin, dienogest, induce apoptosis of human primary cultures of adenomyotic stromal cells[J]. Eur J Obstet Gynecol Reprod Biol, 2014, 179:170-174. doi: 10.1016/j.ejogrb.2014.05.031. pmid: 24953822
[30]	Takeuchi A, Koga K, Miyashita M, et al. Dienogest reduces proliferation, NGF expression and nerve fiber density in human adenomyosis[J]. Eur J Obstet Gynecol Reprod Biol, 2016, 207:157-161. doi: 10.1016/j.ejogrb.2016.10.053. pmid: 27865118
[31]	Prathoomthong S, Tingthanatikul Y, Lertvikool S, et al. The Effects of Dienogest on Macrophage and Natural Killer Cells in Adenomyosis: A Randomized Controlled Study[J]. Int J Fertil Steril, 2018, 11(4):279-286. doi: 10.22074/ijfs.2018.5137. pmid: 29043703
[32]	Ota I, Taniguchi F, Ota Y, et al. A controlled clinical trial comparing potent progestins, LNG-IUS and dienogest, for the treatment of women with adenomyosis[J]. Reprod Med Biol, 2021, 20(4):427-434. doi: 10.1002/rmb2.12408. pmid: 34646070
[33]	Guo W, Lin Y, Hu S, et al. Compare the Efficacy of Dienogest and the Levonorgestrel Intrauterine System in Women with Adenomyosis[J]. Clin Ther, 2023, 45(10):973-976. doi: 10.1016/j.clinthera.2023.07.019.
[34]	Choudhury S, Jena SK, Mitra S, et al. Comparison of efficacy between levonorgestrel intrauterine system and dienogest in adenomyosis: a randomized clinical trial[J]. Ther Adv Reprod Health, 2024,18:26334941241227401. doi: 10.1177/26334941241227401.
[35]	Hassanin AI, Youssef AA, Yousef AM, et al. Comparison of dienogest versus combined oral contraceptive pills in the treatment of women with adenomyosis: A randomized clinical trial[J]. Int J Gynaecol Obstet, 2021, 154(2):263-269. doi: 10.1002/ijgo.13600. pmid: 33454995
[36]	Chan IS, Hsu TF, Shih YC, et al. Maintenance dienogest therapy following adjuvant gonadotropin-releasing hormone agonist treatment after uterus-sparing surgery in adenomyosis: A retrospective cohort study[J]. Int J Gynaecol Obstet, 2023, 161(3):751-759. doi: 10.1002/ijgo.14635.
[37]	Ota K, Takahashi T, Shiraishi S, et al. Combination of microwave endometrial ablation and postoperative dienogest administration is effective for treating symptomatic adenomyosis[J]. J Obstet Gynaecol Res, 2018, 44(9):1787-1792. doi: 10.1111/jog.13720.
[38]	Neriishi K, Hirata T, Fukuda S, et al. Long-term dienogest administra- tion in patients with symptomatic adenomyosis[J]. J Obstet Gynaecol Res, 2018, 44(8):1439-1444. doi: 10.1111/jog.13674.
[39]	Chen CH, Lin YH, Lee CY, et al. Long-term clinical outcomes of dienogest for perimenopausal women with symptomatic adenomyosis[J]. Sci Rep, 2025, 15(1):8174. doi: 10.1038/s41598-025-93156-5.
[40]	Miao J, Lu J, Tang J, et al. Long-term treatment of dienogest with symptomatic adenomyosis: retrospective analysis of efficacy and safety in clinical practice[J]. Gynecol Endocrinol, 2022, 38(8):656-660. doi: 10.1080/09513590.2022.2098948.
[41]	Lin S, Chen Y, Yi J, et al. Dienogest treatment of symptomatic adenomyosis: An in-depth meta-analysis[J]. Eur J Obstet Gynecol Reprod Biol, 2025, 305:365-374. doi: 10.1016/j.ejogrb.2024.12.048. pmid: 39754909

地诺孕素治疗子宫腺肌病相关性疼痛的研究进展

Research Progress on the Treatment of Adenomyosis-Related Pain with Dienogest

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 41

相关文章 15

编辑推荐

Metrics

本文评价

[1]	李飞艳, 朱从心, 李咏, 孙丽, 刘瑜. LNG-IUS固定术治疗子宫腺肌病期间发生大出血致重度贫血一例[J]. 国际妇产科学杂志, 2025, 52(3): 271-274.
[2]	毛逍, 曲冬颖. 妊娠合并心脏病母婴风险评估及管理的研究进展[J]. 国际妇产科学杂志, 2025, 52(3): 286-292.
[3]	冷芹, 钟晓玲, 于威威. 美国母胎医学会《无自然早产史女性短子宫颈的管理指南（2024）》解读[J]. 国际妇产科学杂志, 2025, 52(3): 315-318.
[4]	连思晗, 韩梦菲, 王玉珏, 赵琳燕, 胡燕. E3泛素连接酶在宫颈癌中的研究进展[J]. 国际妇产科学杂志, 2025, 52(3): 319-325.
[5]	冯晓宇, 闫丽隽. 共济失调毛细血管扩张突变和Rad3相关蛋白在卵巢癌发生发展及治疗中的应用[J]. 国际妇产科学杂志, 2025, 52(3): 331-336.
[6]	江文静, 丁勇利, 吕群, 谢蕙霞, 李若芃, 周敏. 青年女性巨大卵巢平滑肌瘤一例[J]. 国际妇产科学杂志, 2025, 52(3): 350-353.
[7]	陈晓娟, 张艳馨. 妊娠合并血友病A患者足月分娩一例[J]. 国际妇产科学杂志, 2025, 52(2): 158-160.
[8]	张昊晟, 魏芳. Nectin-4在妇科恶性肿瘤中的研究进展[J]. 国际妇产科学杂志, 2025, 52(2): 165-168.
[9]	林环宇, 邵小光, 路旭宏, 王秋月, 魏巍, 佟春艳. Web of Science核心数据库2004—2024年女性恶性肿瘤患者生育力保存的研究现状及热点[J]. 国际妇产科学杂志, 2025, 52(2): 180-186.
[10]	殷婷, 丛慧芳. 子宫内膜异位症与痛觉敏化的免疫学研究进展[J]. 国际妇产科学杂志, 2025, 52(2): 206-210.
[11]	江爱美, 张信美. 腹壁子宫内膜异位症的治疗进展[J]. 国际妇产科学杂志, 2025, 52(2): 211-216.
[12]	白耀俊, 王思瑶, 令菲菲, 张森淮, 李红丽, 刘畅. Trop-2及靶向Trop-2抗体偶联药物在妇科恶性肿瘤中的应用进展[J]. 国际妇产科学杂志, 2025, 52(1): 1-7.
[13]	侯春艳, 杜秀萍. 妊娠中晚期自发性子宫破裂二例[J]. 国际妇产科学杂志, 2025, 52(1): 110-113.
[14]	钟佩蕖, 招丽坚, 邹欣欣. 残角子宫妊娠行期待治疗至妊娠晚期一例[J]. 国际妇产科学杂志, 2025, 52(1): 114-116.
[15]	潘琪, 冯同富, 金晶, 吴莺, 杜欣. 腹腔镜切除成人腹膜后巨大成熟性畸胎瘤一例[J]. 国际妇产科学杂志, 2025, 52(1): 28-31.